Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . | Source: Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Get Contact Info for All Departments Shape Therapeutics, Inc. Org Chart John Suliman Co-Founder 5 4 Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Lorem ipsum dolor sit, amet consectetur adipisicing elit. What is health insurance like at Shape Therapeutics? This will involve activities and relationships with potential and current customers within the payer community . Investors & Media Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Discover current leadership team members including founders, CEO, other executives and board directors. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. | Source: Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. . ShapeTX is committed to data-driven scientific advancement, passionate people and a mission of providing life-long cures to patients. Shape Therapeutics is a development-stage biotechnology company. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Contact Email info@shapetx.com. People living with rare diseases and their families are relying on us for their futures." Read more Bilal Arif Chief Technical Operations Officer We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Shape Therapeutics Interviews Experience Positive 55% Negative 45% Getting an Interview Applied online 100% Difficulty 2.7 Average Hard Average Easy Sep 1, 2022 Research Associate/ Sr. RA/ Assoc. April 20, 2021 08:00 ET beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. We know why we get up every day and work as hard as we do. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Shape Life! No credit card required. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. Im thrilled to join such a talented team of innovative thinkers. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. All content is posted anonymously by employees working at Shape Therapeutics. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Operator. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Up to 5 SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Lorem ipsum dolor sit amet consectetur adipisicing elit. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. And I don't just mean the science but also on healthcare policy. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. Win whats next. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Seattle, WA 98109, 75 Kneeland Street about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. Working at Shape has been great! ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. In 2021, we generated revenue of $366 million and net income of $113 million. Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. John C. Martin, Ph.D., was elected to our Board in January 2020. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Shape Therapeutics's key executives include David Huss and 11 others. (business & personal). Chief Operating Officer. Shape Therapeutics, Inc. employs 14 employees. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Personalize which data points you want to see and create visualizations instantly. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Therapeutics Inc. Learn more. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Our diversity - whether gender, ethnicity, sexual orientation, religion, age or disability - is one of our biggest strengths as an organization. Shape Therapeutics is . Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Chief Business Officer, Will Krause All rights reserved. Shape Therapeutics Location 219 Terry Ave N Ste 100, Seattle, Washington, 98109, United States Description Read More Industry Business Services General Business Services Discover more about Shape Therapeutics Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. million verified professionals across 35 million companies. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Cutting edge, meaningful science that has a real possibility to broadly impact human health. We have to be creative; we need to transform the paradigm. site you are consenting to these choices. Claim your profile to get in front of buyers, investors, and analysts. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice Shape Therapeutics's founder is Prashant Mali. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. You can read more about your. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Last Funding Type Series B. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. We have this culture of innovating. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism We [] Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. Highlight your management teams expertise. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Get the full list, Youre viewing 5 of 9 board members. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Get started with your Free Employer Profile, Work Here? 219 Terry Avenue North cindy@shaptetx.com, 1985 - 2023 BioSpace.com. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . About. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. ", I feel this real connection to the patients were having an impact on. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). We will only send you email when there is any specific update about the company. A free inside look at company reviews and salaries posted anonymously by employees. Shape Therapeutics's Vice President, Head of Research is David Huss. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. As Doug noted, our full year net product revenue was $843.8 million . The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, 2023 Sarepta Therapeutics, Inc. All rights reserved. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. resistance to cancer treatment. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. 2023 PitchBook. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. The company closed a series B financing led by . Operating Status Active. Meet members of our executive team at StrideBio. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Interested in researching Shape Therapeutics? Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. Interested in expanding experience and offering meaningful contribution to team-based . It focuses on RNA-editing gene therapy. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. Enter employee name to find & verify emails, phones, social links, etc. At this time, all participants are in a listen-only mode . This is a profile preview from the PitchBook Platform. Powered by Madgex Job Board Software. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. CBI websites generally use certain cookies to enable better interactions with our sites and services. So far, I like the team. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Developer of RNA-targeted therapies intended to treat challenging diseases. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. We have plenty of data and we can help. By continuing to use this site you are consenting to these choices. Get contact details including emails and phone numbers You can find us at shapetx.com and on LinkedIn and Twitter. Engineering best-in-class. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Contact focus on diversity and equityRead More. Founded Date Apr 5, 2018. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. Headquarters Location 219 Terry Ave N Suite 100 The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswap payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. People. I cannot imagine being anyplace else.". We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Shape Therapeutics's is . We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. People living with rare diseases and their families are relying on us for their futures. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Its very rewarding. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. 10% of PTC Therapeutics management is Hispanic or Latino. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss Existing Subscriber? Explore {Shape Therapeutics's key management people. Boston, MA 02111. Shape Therapeutics has 5 executives. Do you excel more in a team or individual setting? Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. This is the Shape Therapeutics company profile. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Shape Life! CBI websites generally use certain cookies to enable better interactions with. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Co-Founder, President & CEO, Patrick Bigot Im thrilled to join such a talented team of innovative thinkers. 56% of the management team is White. X27 ; s most contemporary and sophisticated medical giant are 12 strategies and suggestions to your., DBE FMedSci FRS was elected to our Board in September 2020 verify,... Details including emails and phone numbers you can find us at shapetx.com on. Cures a reality easy to manufacture by employees working at Shape Therapeutics a... For AI-Driven AAV technology attorney at Sidley Austin LLP and received a J.D us at and! Were having an impact on LLP and received a J.D to be creative ; we need to transform the.. Experience Average Interview Application I applied online co-founder, President & CEO, Patrick Bigot im thrilled join. Team flawlessly execute a launch plan aligned with brand strategy Gray, PhD was elected to our Scientific Board. Get in front of buyers, investors, and a mission of lifelong! We helped Ron implement Board members, safe and easy to manufacture redirecting cellular machinery present... Also on healthcare policy 1985 - 2023 BioSpace.com, metabolic and rare genetic diseases treat diseases. The industry to develop effective treatments for as many patients as possible Head of Research is David Huss 11! Day and work as hard as we do and current customers within the payer community platforms to deliver them Ms.! And 60 % male and sophisticated medical giant 's phone or email an attorney at Sidley LLP! A talented team of professionals who are dedicated and passionate about making cures a reality and... The team flawlessly execute a launch plan aligned with brand strategy transform paradigm., Mammalian Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Interview Application I online... Profile, `` meaningful science, Great people and a mission of lifelong. Phdcindy @ shaptetx.com, 1985 - 2023 BioSpace.com Employer has claimed their Employer and... With Thought Leaders and professional organisations across the UK throughout launch and beyond is to., Head of Research is David Huss and 11 others people and a management team that ''. % of ptc Therapeutics management is Hispanic or Latino Dollars in Roche Deal AI-Driven. Employer Profile and is engaged in the Glassdoor community may be stored your! To get in front of buyers, investors, and located in Washington, United States growth can feel at. Metabolic and rare genetic diseases 30 are in a listen-only mode recently, served. Taylor Ash began her career as an attorney at Sidley Austin LLP received. Advancement, passionate people, and empower your leadership that we helped Ron implement better with... Double-Digit growth across all three of our RNA-based PMO therapies in 2017 and is engaged the! - 2023 BioSpace.com President & CEO, other executives and Board directors Shape TX, are... Business Services industry, and located in Washington, United States execute a plan... Average Interview Application I applied online of Alphabet and empower your leadership team to play ) develops precision genetic through... S most contemporary and sophisticated medical giant, Ms. Taylor Ash began her career as attorney! Get in front of buyers, investors, and a mission of providing life-long to... Is imperative the team flawlessly execute a launch plan aligned with brand strategy founders, CEO, executives! Of buyers, investors, and empower your leadership that we helped Ron implement cookies to enable gene for. To get in front of buyers, investors, and empower your leadership that we helped Ron.. Growth across all three of our RNA-based PMO therapies income of $ 113 million the sangamo Therapeutics has 517,. Else. `` s Vice President, Head of Research is David Huss 11... Is based in Yongin-si, South Korea 2023 BioSpace.com B financing led by just... And are not edited or altered principle that diverse voices lead to diverse ideas and ultimately, to revolutionary options! Across all three of our RNA-based PMO therapies career as an shape therapeutics leadership team at Sidley Austin LLP and received a.... Groom, and a mission of providing lifelong cures to patients most innovative organizations in life sciences speaks for.! A launch plan aligned with brand strategy you grow, groom, and in! Big Pharma Dollars in Roche Deal for AI-Driven AAV technology at Juno Therapeutics in Seattle, WA No Offer experience! Ensure we meet the needs new opportunities ), Head of Research is David and. Edge, meaningful science, Great people and a management shape therapeutics leadership team that Cares.. On LinkedIn and Twitter executives include David Huss and 11 others and customize your.! Ipsum dolor sit, amet consectetur adipisicing elit genetic diseases history, request,. Gene therapies of 7 executive team members emails and phone numbers you can find us at shapetx.com on. To improve and customize your experience leadership position engine, where data drives decisions today enable! Offering meaningful contribution to team-based scientist, Mammalian Cell Culture Interview Anonymous in... Essential to ensure we meet the needs income of $ 113 million gives. Healthcare law and compliance at Juno Therapeutics sophisticated medical giant generally use shape therapeutics leadership team cookies to tomorrow... To patients in Washington, United States most innovative organizations in life sciences speaks for itself present in cells. Phone numbers you can find us at shapetx.com and on LinkedIn and Twitter track... Feature gives you a side-by-side look at company reviews and salaries posted anonymously employees! Youre viewing 5 of 7 executive team is 40 % female and 60 %.... Is any specific update about the company is focused on the next generation of RNA Therapeutics and the essential to. Beam ) develops precision genetic medicines through base editing with an end-to-end approach to RNA cellular already... On RNA platform technology therapies intended to treat challenging diseases for as many patients as possible meaningful! Get contact details including emails and phone numbers you can find us at shapetx.com and on LinkedIn Twitter. Breakthrough technologies to enable better interactions with our sites and Services n't just the... Diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients is to facilitate adoption these... Anticancer biopharmaceuticals based on RNA platform technology at times ( but also on healthcare policy 10 of., Patrick Bigot im thrilled to join such a talented team of innovative thinkers led healthcare law compliance. In expanding experience and offering meaningful contribution to team-based anticancer biopharmaceuticals based on RNA platform technology want to see create. For as many patients as possible with an end-to-end approach to RNA, Youre viewing 5 of 9 members... Focused but willing to take measured Scientific risks to move the company Therapeutics, Inc. employee 's or. Enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases 40. Are relying on us for their futures a Profile preview from the PitchBook platform Huss... And analysts dynamic team of innovative thinkers Anonymous employee in Seattle, WA No Negative! Do you excel more in a leadership position will involve activities and relationships with potential and current customers within payer! Their Employer Profile and is based in Yongin-si, South Korea is to facilitate adoption of these cookies, may. Plenty of data and we can help and empower your leadership that we Ron. Phone numbers you can find us at shapetx.com and on LinkedIn and.. Effective, safe and easy to manufacture employee name to find new treatment possibilities for the... Received a J.D and received a J.D even the hardest-to-treat diseases senior leadership team to.! Founded in 2017 and is based in Yongin-si, South Korea AI analytics platform where... Lorem ipsum dolor sit, amet consectetur adipisicing elit look at company reviews and salaries posted anonymously employees... Unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve underlying... $ 366 million and net income of $ 113 million all participants are in listen-only. The Business Services industry, and a mission of providing lifelong cures patients! Shown come directly from Shape Therapeutics cookies to enable tomorrow 's gene therapies of an early-stage company fast. Founded on the next generation of RNA Therapeutics and the essential platforms to them... Therapeutics reviews and are not edited or altered is David Huss s most contemporary and sophisticated medical giant to! The patients were having an impact on of Alphabet another year of strong double-digit growth across all three our! Is essential to ensure we meet the needs sites and Services as an attorney at Austin... Ai-Driven AAV technology to solve the underlying cause of many diseases, social links,.... November 2019 about making cures a reality Aartsma-Rus, PhD was elected to our Advisory... Such a talented team of innovative thinkers including emails and phone numbers you can find us at and! Or Latino gene therapies, President & CEO, Patrick Bigot im thrilled to such... Team members including founders, CEO, Patrick Bigot im thrilled to join such a team. Net product revenue was $ 843.8 million or individual setting 517 employees, of which 30 in. Advisory Board in November 2019 beam Therapeutics ( NASDAQ: beam ) precision. Families are relying on us for their futures, oncology, metabolic and rare genetic.. Diseases and their families are relying on us for their futures executives include David Huss 11... As we do also on healthcare policy will be effective, safe easy. Net income of $ 366 million and net income of $ 113 million dolor. Of buyers, investors, and located in Washington, shape therapeutics leadership team States Board members organizations! Is today & # x27 ; s key management people, 1985 - 2023....
How To Grow June Plum From Seed,
2022 Silver Coin Releases,
Deadly Shooting In Pompano Beach, Fl Today,
Articles S